A Phase 1 interventional study of Andecaliximab and S-1 in Gastric Adenocarcinoma, sponsored by Gilead Sciences. Terminated at 3 sites in Japan. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2020-12-24.
Sponsored by Gilead Sciences · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with anti-cancer agents in Japanese participants with inoperable advanced or recurrent gastric or recurrent gastroesophageal junction (GEJ) adenocarcinoma.
Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.
Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.
Counted across the registry records on this site, refreshed daily.
Key Inclusion Criteria:
In addition to the applicable criteria above, participants in Cohort 4 must meet additional inclusion criteria to be eligible for participation in this study:
Key Exclusion Criteria:
In addition to the applicable criteria above, participants in Cohort 4 who meet any of the following exclusion criteria will not be enrolled in this study
NOTE: Other protocol defined Inclusion/ Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive andecaliximab (ADX) 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab
Participants will receive ADX 800 mg every 2 weeks on Days 1 and 15 of each 28-day treatment cycle in combination with S-1 orally twice daily plus cisplatin chemotherapy (dosage and regimen will be based on participant condition, investigator discretion, institutional practice, and/or the in-country label) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: S-1 · Drug: Cisplatin
Participants will receive ADX 1200 mg every 3 weeks on Day 1 of each 21-day treatment cycle in combination with chemotherapy (S-1 80 mg/day to 120 mg/day according to the body surface area orally twice daily for first 14 days of 21 day cycle plus oxaliplatin 100 mg/m\^2) until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study.
Drug: Andecaliximab · Drug: S-1 · Drug: Oxaliplatin
Participants will receive ADX 800 mg every 2 weeks followed by chemotherapy (nivolumab 3 mg/kg) on Days 1 and 15 of each 28-day treatment cycle until disease progression, unacceptable toxicity, withdrawal of consent, or other reasons prespecified in the protocol for discontinuation of study drug.
Drug: Andecaliximab · Drug: Nivolumab
Administered via intravenous (IV) infusion (approximately 30 minutes)
Also known as: GS-5745
Drug pages: Tegafur · Gimeracil · Oxonic Acid
Administered orally
Administered via IV infusion on Day 8 of every 5 weeks
Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle
Administered via IV infusion (approximately 60 minutes) every 2 weeks
Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)
TEAEs are any AEs with an onset date of on or after the date that ADX and if applicable, nivolumab was first administered and no later than 30 days after permanent discontinuation of ADX, or if applicable, 5 months after permanent discontinuation of nivolumab (whichever is later).
Time frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the specified time frame (first dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)) was considered treatment-emergent.Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 was used for assigning toxicity grades to laboratory results for analysis.
Time frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)
Cohort 1: Plasma Concentration of Andecaliximab
Plasma concentration is defined as the measured drug concentration. Blood samples were drawn at pre-dose and 30 (±15) minutes after infusion on Day 1 of Cycles 2, 3, 5; End of study (EOS) (3 years and 1 month); Cycle 1 only: 30 (±15) minutes after infusion on Day 1; anytime on Day 2, 4, and 8; pre-dose and 30 (±15) minutes post infusion on Day 15. The duration of each cycle for Cohort 1, 2, and 4 was 28 days and for Cohort 3 was 21 days. Infusion duration = 30 to 35 minutes. * min=minutes * D=Days * C=Cycle
Time frame: Pre-dose and 30 (±15) min after infusion on C2D1, C3D1, C5D1; EOS (3 years and 1 month); C1 only: 30 (±15) min after infusion on D1; anytime on D2, D4 and D8; Pre-dose and 30 (±15) minutes post infusion on D15
PK Parameter: Cmax of Andecaliximab
Cmax is defined as the maximum concentration of drug.
Time frame: Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)
PK Parameter: AUClast of Andecaliximab
AUClast is defined as the area under the concentration versus time curve to the last measurable concentration of drug from time zero to the last observable concentration.
Time frame: Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)
PK Parameter: AUC0-336h of Andecaliximab
AUC0-336h is defined as the area under the concentration versus time curve from time zero to time 336 hour.
Time frame: Cycle 1 only: 30 (± 15) minutes after the end of infusion on Day 1; anytime on Days 2, 4, and 8; prior to dosing on Day 15 (Cycle length= 28 days) (infusion duration= 30 to 35 minutes)
Number of Participants With Positive Anti-Andecaliximab Antibodies
Time frame: Pre-dose on Day 1 of Cycles 1, 2, 3, 5, 7 and every third cycle and anytime at EOT (82.4 weeks) and EOS visit (maximum: 3 years and 1 month) (Each Cycle= 28 days for Cohort 1, 2 and 4; 21 days for Cohort 3)
Participants were enrolled at study sites in Japan. The first participant was screened on 20 Sep 2016. The last study visit occurred on 25 Oct 2019.
| Milestone | Cohort 1: ADX | Cohort 2: ADX + S-1 + Cisplatin | Cohort 3: ADX + S-1 + Oxaliplatin | Cohort 4: ADX + Nivolumab |
|---|---|---|---|---|
| Started | 9 | 6 | 10 | 11 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 9 | 6 | 10 | 11 |
| Withdrew: Death | 7 | 3 | 2 | 5 |
| Withdrew: Study terminated by sponsor | 1 | 3 | 8 | 5 |
| Withdrew: Enrolled, not treated | 1 | 0 | 0 | 1 |
TEAEs are any AEs with an onset date of on or after the date that ADX and if applicable, nivolumab was first administered and no later than 30 days after permanent discontinuation of ADX, or if applicable, 5 months after permanent discontinuation of nivolumab (whichever is later).
| percentage of participants | Cohort 1: ADX | Cohort 2: ADX + S-1 + Cisplatin | Cohort 3: ADX + S-1 + Oxaliplatin | Cohort 4: ADX + Nivolumab |
|---|---|---|---|---|
| Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs) | 100.0 | 100.0 | 100.0 | 100.0 |
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. If the relevant baseline laboratory value was missing, then any abnormality of at least Grade 1 observed within the specified time frame (first dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)) was considered treatment-emergent.Common Terminology Criteria for Adverse Events (CTCAE) version 4.03 was used for assigning toxicity grades to laboratory results for analysis.
| percentage of participants | Cohort 1: ADX | Cohort 2: ADX + S-1 + Cisplatin | Cohort 3: ADX + S-1 + Oxaliplatin | Cohort 4: ADX + Nivolumab |
|---|---|---|---|---|
| Any Laboratory abnormalities: Hematology | 87.5 | 83.3 | 90.0 | 70.0 |
| Any Laboratory abnormalities: Chemistry | 100.0 | 100.0 | 100.0 | 80.0 |
| Any Laboratory abnormalities: Coagulation | 0 | 0 | 0 | 10.0 |
Plasma concentration is defined as the measured drug concentration. Blood samples were drawn at pre-dose and 30 (±15) minutes after infusion on Day 1 of Cycles 2, 3, 5; End of study (EOS) (3 years and 1 month); Cycle 1 only: 30 (±15) minutes after infusion on Day 1; anytime on Day 2, 4, and 8; pre-dose and 30 (±15) minutes post infusion on Day 15. The duration of each cycle for Cohort 1, 2, and 4 was 28 days and for Cohort 3 was 21 days. Infusion duration = 30 to 35 minutes. * min=minutes * D=Days * C=Cycle
| nanograms per milliliter | Cohort 1: ADX |
|---|---|
| 30 minutes Postdose: Cycle 1 Day 1 | 262,625.0 ± 57410.64 |
| Postdose: Cycle 1 Day 2 | 211,875.0 ± 56688.21 |
| Postdose: Cycle 1 Day 4 | 133,100.0 ± 57485.39 |
| Postdose: Cycle 1 Day 8 | 90100.0 ± 18127.25 |
| Predose: Cycle 1 Day 15 | 54800.0 ± 12011.66 |
| 30 minutes Postdose: Cycle 1 Day 15 | 310,971.4 ± 128,365.39 |
| Predose: Cycle 2 Day 1 | 122,200.0 ± 52872.68 |
| 30 minutes Postdose: Cycle 2 Day 1 | 458,666.7 ± 211,613.64 |
| Predose: Cycle 3 Day 1 | 158,000.0 ± 16970.56 |
| 30 minutes Postdose: Cycle 3 Day 1 | 349,300.0 ± 402,626.60 |
| Predose: Cycle 5 Day 1 | 154,500.0 ± 6363.96 |
| 30 minutes Postdose: Cycle 5 Day 1 | 510,500.0 ± 136,471.61 |
| End of study | 61960.0 ± 37635.40 |
Cmax is defined as the maximum concentration of drug.
| micrograms per milliliter | Cohort 1: ADX |
|---|---|
| PK Parameter: Cmax of Andecaliximab | 264.0 ± 56.42 |
AUClast is defined as the area under the concentration versus time curve to the last measurable concentration of drug from time zero to the last observable concentration.
| hours*micrograms per milliliter(h*μg/mL) | Cohort 1: ADX |
|---|---|
| PK Parameter: AUClast of Andecaliximab | 33500.2 ± 8397.01 |
AUC0-336h is defined as the area under the concentration versus time curve from time zero to time 336 hour.
| h*μg/mL | Cohort 1: ADX |
|---|---|
| PK Parameter: AUC0-336h of Andecaliximab | 34341.9 ± 8697.66 |
| Participants | Cohort 1: ADX | Cohort 2: ADX + S-1 + Cisplatin | Cohort 3: ADX + S-1 + Oxaliplatin | Cohort 4: ADX + Nivolumab |
|---|---|---|---|---|
| Number of Participants With Positive Anti-Andecaliximab Antibodies | 0 | 0 | 0 | 0 |
Collected over Adverse Events: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab) All-Cause Mortality: From study start date up to study completion date (3 years and 1 month). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Cohort 1: ADX | 7/8 (87.5%) | 2/8 (25%) | 8/8 (100%) |
| Cohort 2: ADX + S-1 + Cisplatin | 3/6 (50%) | 2/6 (33.3%) | 6/6 (100%) |
| Cohort 3: ADX + S-1 + Oxaliplatin | 2/10 (20%) | 1/10 (10%) | 10/10 (100%) |
| Cohort 4: ADX + Nivolumab | 5/10 (50%) | 5/10 (50%) | 10/10 (100%) |
| Event | Cohort 1: ADX | Cohort 2: ADX + S-1 + Cisplatin | Cohort 3: ADX + S-1 + Oxaliplatin | Cohort 4: ADX + Nivolumab |
|---|---|---|---|---|
| Hepatic function abnormalHepatobiliary disorders | 0/8 | 1/6 | 0/10 | 0/10 |
| Decreased appetiteMetabolism and nutrition disorders | 1/8 | 1/6 | 0/10 | 0/10 |
| Back painMusculoskeletal and connective tissue disorders | 0/8 | 1/6 | 0/10 | 0/10 |
| HydronephrosisRenal and urinary disorders | 1/8 | 0/6 | 0/10 | 0/10 |
| AnaemiaBlood and lymphatic system disorders | 0/8 | 0/6 | 0/10 | 1/10 |
| MalaiseGeneral disorders | 0/8 | 0/6 | 0/10 | 1/10 |
| PyrexiaGeneral disorders | 0/8 | 0/6 | 0/10 | 1/10 |
| Bile duct stenosisHepatobiliary disorders | 0/8 | 0/6 | 1/10 | 0/10 |
| CholangitisHepatobiliary disorders | 0/8 | 0/6 | 0/10 | 1/10 |
| Blood bilirubin increasedInvestigations | 0/8 | 0/6 | 0/10 | 1/10 |
| Event | Cohort 1: ADX | Cohort 2: ADX + S-1 + Cisplatin | Cohort 3: ADX + S-1 + Oxaliplatin | Cohort 4: ADX + Nivolumab |
|---|---|---|---|---|
| Peripheral sensory neuropathyNervous system disorders | 0/8 | 1/6 | 10/10 | 1/10 |
| NauseaGastrointestinal disorders | 4/8 | 5/6 | 4/10 | 2/10 |
| Decreased appetiteMetabolism and nutrition disorders | 3/8 | 5/6 | 5/10 | 2/10 |
| DiarrhoeaGastrointestinal disorders | 1/8 | 4/6 | 2/10 | 2/10 |
| StomatitisGastrointestinal disorders | 0/8 | 3/6 | 3/10 | 3/10 |
| Neutrophil count decreasedInvestigations | 0/8 | 3/6 | 3/10 | 2/10 |
| Platelet count decreasedInvestigations | 0/8 | 1/6 | 5/10 | 0/10 |
| White blood cell count decreasedInvestigations | 0/8 | 3/6 | 4/10 | 2/10 |
| InsomniaPsychiatric disorders | 0/8 | 3/6 | 0/10 | 1/10 |
| ConstipationGastrointestinal disorders | 2/8 | 2/6 | 4/10 | 1/10 |
The Safety Analysis Set included all participants who took at least 1 dose of study drug.
| Age, Continuous(years) | Cohort 1: ADX | Cohort 2: ADX+S-1+Cisplatin | Cohort 3: ADX+S-1+Oxaliplatin | Cohort 4: ADX+Nivolumab | Total |
|---|---|---|---|---|---|
| Mean | 59 ± 14.7 | 69 ± 7.9 | 56 ± 15.1 | 63 ± 11.8 | 61 ± 13.3 |
| Sex: Female, Male(Participants) | Cohort 1: ADX | Cohort 2: ADX+S-1+Cisplatin | Cohort 3: ADX+S-1+Oxaliplatin | Cohort 4: ADX+Nivolumab | Total |
|---|---|---|---|---|---|
| Female | 3 | 1 | 4 | 1 | 9 |
| Male | 5 | 5 | 6 | 9 | 25 |
| Ethnicity (NIH/OMB)(Participants) | Cohort 1: ADX | Cohort 2: ADX+S-1+Cisplatin | Cohort 3: ADX+S-1+Oxaliplatin | Cohort 4: ADX+Nivolumab | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 0 | 0 |
| Not Hispanic or Latino | 8 | 6 | 10 | 10 | 34 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Cohort 1: ADX | Cohort 2: ADX+S-1+Cisplatin | Cohort 3: ADX+S-1+Oxaliplatin | Cohort 4: ADX+Nivolumab | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 6 | 10 | 10 | 34 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 0 | 0 | 0 | 0 |
| White | 0 | 0 | 0 | 0 | 0 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Sep 2016 to primary completion in Oct 2019, 37 months.
Results were first posted in Dec 2020, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Nov 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Andecaliximab